VIM and scleroderma: The number of Vimentin+p-SMAD3+ myofibroblasts increased in the BLM-induced scleroderma model, and WKYMVm treatment markedly reduced the BLM-induced increase of Vimentin+p-SMAD3+ cell number (Figures 3B,E).